Sustainable rare diseases business and drug access: no time for misconceptions

Legislative incentives enacted in Europe through the Regulation (EC) No. 141/2000 to incentivize orphan drug development have over the last 12 years constituted a powerful impetus toward R&D directed at the rare diseases population. However, despite therapeutic promises contained in these projec...

Descripción completa

Detalles Bibliográficos
Autores principales: Rollet, Pierrick, Lemoine, Adrien, Dunoyer, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735431/
https://www.ncbi.nlm.nih.gov/pubmed/23879976
http://dx.doi.org/10.1186/1750-1172-8-109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735431/
https://www.ncbi.nlm.nih.gov/pubmed/23879976
http://dx.doi.org/10.1186/1750-1172-8-109

Ejemplares similares